ClinicalTrials.gg

Program

teprotumumab

Also written as “Teprotumumab”, “RG1507” and “TEPEZZA”.

Its studies are mostly in Graves Ophthalmopathy · Neoplasms · Macular Edema · Scleroderma, Diffuse · Sarcoma, led by 2 companies.

Furthest: phase 4, since Oct 6, 202018 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen121 open or runningphase 4since Oct 6, 2020May 2, 2013none ahead
Hoffmann-La Roche60 open or runningphase 2since Mar 19, 2008Nov 15, 2006none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 4 studies since Nov 15, 2006.

  1. Dec 18, 2008Phase 1 study in NeoplasmsHoffmann-La Roche · NCT00811993 · 104 enrolled · United States
  2. Apr 15, 2009Phase 1 study in Breast NeoplasmsHoffmann-La Roche · NCT00882674 · 8 enrolled · United Kingdom
  3. May 2, 2013Amgen's first study: phase 2 study in Graves OphthalmopathyNew to AmgenAmgen · NCT01868997 · 88 enrolled · United States, Germany, Italy and more
  4. Mar 27, 2014Phase 1 study in Diabetic Macular EdemaAmgen · NCT02103283 · 5 enrolled · United States
  5. Sep 27, 2017Phase 3 study in Graves OphthalmopathyAmgen · NCT03298867 · 83 enrolled · United States, Germany, Italy
  6. Mar 5, 2018Phase 3 study in Graves OphthalmopathyAmgen · NCT03461211 · 51 enrolled · United States, Germany, Italy
  7. Jul 16, 2020Phase 1 study in Scleroderma, DiffuseAmgen · NCT04478994 · 3 enrolled · United States
  8. Oct 6, 2020Phase 4 study in Graves OphthalmopathyAmgen · NCT04583735 · 62 enrolled · United States
  9. Jul 19, 2021Phase 4 study in Graves OphthalmopathyAmgen · NCT05002998 · 313 enrolled · United States, France, Germany and more
  10. Jan 31, 2024Phase 3 study in Graves OphthalmopathyAmgen · NCT06248619 · 89 enrolled · United States, Argentina, Australia and more
  11. Apr 24, 2024Phase 1 study in Graves OphthalmopathyAmgen · NCT06389578 · 16 enrolled · United States
  12. Aug 19, 2024Phase 1 study in Graves OphthalmopathyAmgen · NCT06563856 · 37 enrolled · United States
  13. Nov 4, 2024Phase 1 study in Graves OphthalmopathyAmgen · NCT06674941 · 44 enrolled · United States
  14. Aug 25, 2025Phase 1 study in Graves OphthalmopathyAmgen · NCT07142642 · 20 enrolled · China

TargetBeta

IGF1R →read by rule
“A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor-1 receptor (IGF-1R) ”NCIt, by rule
“Insulin-like growth factor I receptor antagonist”ChEMBL 37, by rule

Other programs on IGF1R

ProgramCompanyFurthest phaseStudies
veligrotugruleviridian-therapeutics-incphase 47
linsitinibruleAstellas Pharmaphase 313
MHB018AruleMinghui Pharmaceuticalphase 36
IBI311ruleInnovent Biologicsphase 35
IBI3031ruleInnovent Biologicsphase 11

Studies

All 18 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07142642Graves Ophthalmopathy · China1CompletedAmgenNov 22, 202520
NCT06674941Graves Ophthalmopathy · United States1CompletedAmgenNov 14, 202344
NCT06563856Graves Ophthalmopathy · United States1CompletedAmgenMay 27, 202137
NCT06389578Graves Ophthalmopathy · United States1CompletedAmgenFeb 28, 202316
NCT06248619Graves Ophthalmopathy · United States, Argentina, Australia and more3Active, not recruitingAmgenDec 23, 202589
NCT05002998Graves Ophthalmopathy · United States, France, Germany and more4CompletedAmgenDec 19, 2025313
NCT04583735Graves Ophthalmopathy · United States4CompletedAmgenMar 17, 202362
NCT04478994Scleroderma, Diffuse · United States1TerminatedAmgenNov 29, 20223
NCT03461211Graves Ophthalmopathy · United States, Germany, Italy3CompletedAmgenJun 8, 202051
NCT03298867Graves Ophthalmopathy · United States, Germany, Italy3CompletedAmgenFeb 13, 201983
NCT02103283Diabetic Macular Edema · United States1CompletedAmgenAug 20165
NCT01868997Graves Ophthalmopathy · United States, Germany, Italy and more2CompletedAmgenMar 201688
NCT00882674Breast Neoplasms · United Kingdom1CompletedHoffmann-La RocheDec 20108
NCT00811993Neoplasms · United States1TerminatedHoffmann-La RocheDec 2012104
NCT00773383Carcinoma, Non-Small-Cell Lung · United States, Canada, France and more2TerminatedHoffmann-La RocheFeb 201035
NCT00642941Sarcoma · United States, Australia, Canada and more2TerminatedHoffmann-La RocheFeb 19, 2014317
NCT00560144Neoplasms · United States1CompletedHoffmann-La RocheDec 201134
NCT00400361Neoplasms · United States1CompletedHoffmann-La RocheApr 201198

How it is read

Names in the registry

  • “Teprotumumab”, 8 entries
  • “RG1507”, 8 entries
  • “TEPEZZA”, 3 entries
  • “teprotumumab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.